Extended Data Fig. 3: Transcriptomic modifiers of sotorasib efficacy.
From: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
(a) Prevalence of transcriptional subtypes across CB100 and CB200 studies as noted. (b) Pooled TTF1 expression distribution (TTF1low or TTF1high) using K-means in patients from the combined dataset (CB100 + CB200 sotorasib and docetaxel arms). (c) Prevalence of TTF1low and TTF1high tumors, across CB100 and CB200 studies. (d) Kaplan-Meier curve of OS across KC, KL, and KP tumor types for patients treated with sotorasib or docetaxel in CB200. (e) Prevalence of patients with fast progression or long-term benefit across KC, KL, and KP tumor types for patients treated with sotorasib from the combined dataset. (f, g) Kaplan-Meier curves of (f) PFS and (g) OS across KC and KL/KP tumor types based on TTF1 expression for patients treated with sotorasib in the combined dataset. (h, i) Kaplan-Meier curves of (h) PFS and (i) OS based on TTF1 expression for patients treated with sotorasib or docetaxel in CB200. CB100, CodeBreaK 100; CB200, CodeBreaK 200; KRAS, Kirsten rat sarcoma virus; OS, overall survival; PFS, progression-free survival; RNA-seq, RNA sequencing; TTF-1, thyroid transcription factor-1.
